New drug combo for high-risk neuroblastoma
Part of Cancer clinical trials.
This study tests a new combination of drugs (a GSL synthetase inhibitor, GM-CSF, and possibly an immune checkpoint inhibitor) for people with high-risk neuroblastoma that has already been treated. It aims to see if this combination can help shrink tumors or slow the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 6 years old or older.
- You must have a measurable tumor that can be seen on a scan.
- It has been at least 4 weeks since your last cancer treatment, and any side effects have mostly gone away.
- You are generally able to get up and care for yourself (ECOG score 0-2).
- You are not allergic to Eliglustat or any of the study drugs.
- You do not have a serious active infection.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a vaccine, combined with two other immune-boosting drugs (β-glucan and GM-CSF), to see if it can help keep neuroblastoma from coming back. It's for people who have already completed standard treatment and are in remission.
This trial tests a combination of chemotherapy and immunotherapy as a first treatment for children and young adults with high-risk neuroblastoma. The goal is to see if this approach can improve outcomes.
This trial tests a vaccine combined with a substance called beta-glucan to help the immune system recognize and fight neuroblastoma cells. It is for children who have already completed treatment for high-risk neuroblastoma and are now in remission.
This Phase 3 study tests whether adding either a targeted drug (lorlatinib) or a radioactive treatment (131I-MIBG) to intensive chemotherapy improves outcomes for children with high-risk neuroblastoma. It may help by aiming at tumor cells more directly alongside standard treatment.
This trial tests adding a targeted drug called dinutuximab to standard chemotherapy, surgery, and a stem cell transplant for children and young adults with a new diagnosis of high-risk neuroblastoma. The goal is to see if this combination helps more patients stay in remission.
This trial combines the immunotherapy drug dinutuximab beta with two different chemotherapy regimens to see if it works better for children with high-risk neuroblastoma that has spread. It may be an option for newly diagnosed patients who have not had cancer treatment before.
Hear when a new Neuroblastoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.